Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Borrows €15M to Launch Novodiag Platform, IVD Tests

NEW YORK (GenomeWeb) – Finnish diagnostics developer Mobidiag Oy announced today that it has elected to borrow €15 million ($16.6 million) from the European Investment Bank Group in order to "finalize and scale up" manufacturing, validation, and commercialization of its PCR- and microarray-based Novodiag platform and in vitro diagnostic tests for infectious agents.

"We have now the resources to reach our goals and build significant value over the next years based on our state-of-the-art assays and platforms," CEO Tuomas Tenkanen said in a statement.

Novodiag is a cartridge-based, multiplex assay platform for the rapid detection of infectious agents and antibiotic resistance. The instrument is aimed at small- to medium-sized clinical microbiology laboratories with lower-throughput requirements. Mobidiag is also developing Novodiag assays for gastrointestinal, respiratory, blood, skin, and central nervous system infections.

The loan comes under the InnovFin initiative and is backed by the European Union under Horizon 2020 financial instruments, Mobidiag said in a statement.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.